MannKind (NASDAQ:MNKD) Price Target Increased to $7.50 by Analysts at Cantor Fitzgerald

MannKind (NASDAQ:MNKD – Get Free Report) had its target price upped by equities research analysts at Cantor Fitzgerald from $6.50 to $7.50 in a note issued to investors on Tuesday, Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 41.78% from […]

Related Keywords

Michael Castagna ,Stevenb Binder ,Alfrede Mann ,Proshare Advisors ,Charles Schwab Investment Management Inc ,Securities Exchange Commission ,Great West Life Assurance Co ,Cetera Advisors ,Mannkind Corp ,Cetera Advisor Networks ,Mannkind Company Profile ,Cantor Fitzgerald ,Get Free Report ,Exchange Commission ,West Life Assurance ,Share Advisors ,Advisor Networks ,Charles Schwab Investment Management ,Schwab Investment Management ,Mannkind Daily ,Mannkind ,Nasdaq Mnkd ,Mnkd ,Medical ,56400p20 ,Boost Price Target ,